Zhang, Liyong http://orcid.org/0000-0002-7498-6496
Smyth, David
Al-Khalaf, Mohammad
Blet, Alice http://orcid.org/0000-0003-3885-9569
Du, Qiujiang
Bernick, Jordan
Gong, Michael
Chi, Xu
Oh, Yena
Roba-Oshin, Malaika
Coletta, Elizabeth
Feletou, Michel
Gramolini, Anthony O. http://orcid.org/0000-0003-1109-2070
Kim, Kyoung-Han http://orcid.org/0000-0002-0433-656X
Coutinho, Thais
Januzzi, James L. Jr http://orcid.org/0000-0002-8338-1798
Tyl, Benoit
Ziegler, Andre
Liu, Peter P. http://orcid.org/0000-0002-3017-1199
Funding for this research was provided by:
Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (CGS-D, MOP142471, UI354782)
Heart and Stroke Foundation of Canada (National New Investigator Award)
Ontario Genomics Institute (OGI-080)
Article History
Received: 7 October 2021
Accepted: 2 November 2022
First Online: 22 December 2022
Competing interests
: The project was funded from peer-reviewed Genome Canada and the Ontario Genomic Institute grant ‘Cardiovascular Biomarker Translation 1 and 2’ (OGI-080 and OGI-205) with Roche Diagnostics as a partner. The University of Toronto and Roche Diagnostics share a patent on the ‘Use of IGFBP7 in the assessment of heart failure’ (EP2115477B1, US-10488422_B2) with P.P.L. and A.O.G. as inventors. The University of Ottawa Heart Institute Research Corporation with P.P.L. and L.Z. as inventors hold a patent, ‘Therapeutics targeting IGFBP7 for the treatment or prevention of heart failure and metabolic disease’ (US2018/0127752 A1), on the potential use of anti-IGFBP7 antibody and AAV-IGFBP7 shRNA as therapeutic tools. J.L.J. is a Trustee of the American College of Cardiology; is a board member of Imbria Pharmaceuticals; has received research support from Abbott, Applied Therapeutics, Innolife, Novartis Pharmaceuticals and Roche Diagnostics; has received consulting income from Abbott, Beckman, Bristol Myers Squibb, Boehringer Ingelheim, Janssen, Novartis, Pfizer, Merck, Roche Diagnostics and Siemens; and participates in clinical endpoint committees and data safety monitoring boards for Abbott, AbbVie, Bayer, CVRx, Intercept, Janssen and Takeda. The remaining authors declare no competing interests.